| Theme | New Drugs for Dialysis Patients | |
|---|---|---|
| Title | Review of newly introduced medicine in cardiovascular disease | |
| Publish Date | 2006/06 | |
| Author | Yoshiro Watanabe | Department of Cardiology, Juntendo University, School of Medicine |
| Author | Hiroyuki Daida | Department of Cardiology, Juntendo University, School of Medicine |
| [ Summary ] | Drug-eluting stents (DES), a Rho-kinase inhibitor, and an aldosterone blocker were outlined as new treatments for use in the cardiovascular system. DES, polymers contain medicines coated on to stents. The medicine is discharged at the appropriate time. The rate of restenosis has decreased to 10 % or less with the use of DES. However, problems remain concerning long-term prognoses. The Rho / Rho-kinase system has an important role in the pathogenesis of cardiovascular disease. Therefore, Rho-kinase inhibitors can be used for many cardiovascular conditions, and clinical research is progressing. It is understood that aldosterone has an important role in the pathogenesis of cardiovascular disease. Aldosterone blockers have come to be considered organ protecting drugs in cardiovascular disease. The advancements on the research concerning eplerenon, a new aldosterone blocker are expected. | |